Výzkum a projektyVýzkumné skupiny IBA MU

Výzkumné skupiny IBA MU Analýza klinických dat

Vedoucí výzkumné skupiny Vedoucí výzkumné skupiny: RNDr. Jiří Jarkovský, Ph.D.

Skupina analýzy klinických dat Institutu biostatistiky a analýz MU se významně podílí na řešení řady projektů klinického výzkumu.


Vedoucí výzkumné skupiny:

RNDr. Jiří Jarkovský, Ph.D.

RNDr. Jiří Jarkovský, Ph.D.

Kontakt: jarkovsky@iba.muni.cz

Analýza klinických dat je jednou z hlavních činností IBA MU. Portfolio analýzy dat zahrnuje celou škálu dovedností nezbytných pro komplexní podporu klinických projektů – od návrhu experimentu přes invenční vizualizaci, popisnou statistiku a testování hypotéz až po analýzu cílových parametrů, prediktivní modelování a zpracování vícerozměrných dat.

Výstupem analýzy klinických dat nejsou jen sumární reporty a prezentace, ale také interpretace výsledků opírající se o znalost klinického pozadí projektu a analytické výstupy pro vědecké publikace v impaktovaných zahraničních časopisech.

Vybrané projekty

Analýza dat z klinických registrů

  • Významným zdrojem klinických dat sbíraných na IBA MU jsou klinické registry. Tyto registry spolehlivě popisují klinickou praxi, ať už se zaměřují na sběr a analýzu dat o konkrétních diagnostických či terapeutických postupech, nebo monitorují výsledky specifického typu léčby. IBA MU provozuje desítky klinických registrů České onkologické společnosti ČLS JEP a několika dalších odborných lékařských společností. Hlavním cílem těchto projektů je monitorování a retrospektivní zhodnocení zdravotní péče v oblastech, kde je kladen důraz na efektivitu léčby a zlepšování poskytované péče. Zvláštní pozornost je věnována moderním léčebným postupům, inovativním lékům, ale i projektům zaměřeným na individualizovanou péči.
    http://www.registry.cz

Vybrané publikace

  • Büchler T, Bortlíček Z, Poprach A, et al. Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis. Urologic Oncology: Seminars and Original Investigations 2014; 32(5): 569-575. doi: 10.1016/j.urolonc.2013.12.007.
  • Büchler T, Pavlík T, Melichar B, et al. Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis. BMC Cancer 2014; 14: 323. doi: 10.1186/1471-2407-14-323.
  • Chrapek O, Jarkovský J, Šín M, Studnička J, Kolář P, Jirková B, Dušek L, Pitrová Š, Řehák J. Prognostic factors of early morphological response to treatment with ranibizumab in patients with wet age-related macular degeneration. Journal of Ophthalmology, Article ID 867479.
  • Jansa P, Jarkovský J, Al-Hiti H, et al. Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry. BMC Pulmonary Medicine 2014; 14:45. doi: 10.1186/1471-2466-14-45.
  • Kiss I, Bortlíček Z, Melichar B, et al. Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma. Anticancer Research 2014; 34(2): 949-954.
  • Poprach A, Pavlík T, Melichar B, et al. Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines. Urologic Oncology: Seminars and Original Investigations 2014; 32(4): 488-495. doi: 10.1016/j.urolonc.2013.09.011.
  • Salaj P, Kubes R, Cetkovsky P, et al. Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry. Thrombosis Research 2014; 133(2): 162-167. doi: 10.1016/j.thromres.2013.11.002.
  • Slavíček L, Pavlík T, Tomášek J, et al. Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry. BMC Gastroenterology 2014, 14: 53. doi: 10.1186/1471-230X-14-53.
  • Stourac P, Blaha J, Klozova R, Noskova P, Seidlova D, Brozova L, Jarkovsky J. Anesthesia for Cesarean Delivery in the Czech Republic: A 2011 National Survey. Anesthesia & Analgesia 2014 [Epub ahead of print] doi: 10.1213/ANE.0000000000000572.
  • Toušek P, Toušek F, Horák D, et al. The incidence and outcomes of acute coronary syndromes in a central European country: results of the CZECH-2 registry. International Journal of Cardiology 2014; 173(2): 204-208. 10.1016/j.ijcard.2014.02.013.
  • Václavík J, Špinar J, Vindiš D et al. ECG in patients with acute heart failure can predict in-hospital and long-term mortality. Internal and Emergency Medicine 2014, 9(3): 283-291. doi: 10.1007/s11739-012-0862-1.
  • Vyskocilova K, Spinarova L, Spinar J, et al. Prevalence and clinical significance of liver function abnormalities in patients with acute heart failure. Biomedical Papers 2014, doi: 10.5507/bp.2014.014. [Epub ahead of print]
  • Bladen CL, Rafferty K, Straub V, et al. The TREAT-NMD duchenne muscular dystrophy registries: Conception, design, and utilization by industry and academia. Human Mutation 2013; 34(11): 1449-1457. doi: 10.1002/humu.22390.
  • Bladen, CL, Thompson, R, Jackson, JM, et al. Mapping the differences in care for 5,000 Spinal Muscular Atrophy patients, a survey of 24 national registries in North America, Australasia and Europe. Journal of Neurology 2013; 261(1):152-163. doi: 10.1007/s00415-013-7154-1.
  • Fiala O, Pešek M, Fínek J,et al. Erlotinib in the treatment of advanced squamous cell NSCLC. Neoplasma 2013, 60 (6): 676-682. doi: 10.4149/neo_2013_086.
  • Fiala O, Pešek M, Fínek J, et al. Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice. Neoplasma 2013, 60 (1): 26-32. doi: 10.4149/neo_2013_004.
  • Horák P, Skácelová M, Hejduk K, et al. Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic – data from the ATTRA registry. Clinical Rheumatology 2013; 32:1451-1458. doi: 10.1007/s10067-013-2303-6.
  • Hronek M, Kovařík M, Aimová P, et al. Skinfold anthropometry – the accurate method for fat free mass measurement in COPD. COPD 2013; 10(5): 597-603. doi: 10.3109/15412555.2013.781151.
  • Klamová H, Machová Poláková K, Mužík J, et al. Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cut-off levels. Cancer Medicine 2013; 2(2): 216-225. doi: 10.1002/cam4.59.
  • Koblížek V, Chlumský J, Zindr V, et al. Chronic obstructive pulmonary disease: official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care. Biomedical Papers 2013; 157(2): 189-201. doi: 10.5507/bp.2013.039.
  • Pavlík, T, Janoušová, E, Mayer, J, et al. Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications. American Journal of Hematology 2013; 88(9): 790-797. doi: 10.1002/ajh.23508.
  • Studnička J, Říhová B, Rencová E, et al. Cost and effectiveness of therapy for wet age-related macular degeneration in routine clinical practice. Ophthalmologica 2013; 230(1): 34-42. doi: 10.1159/000350802.
  • Büchler T, Klapka R, Melichar B, et al. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry. Annals of Oncology 2012; 23(2): 395–401. doi: 10.1093/annonc/mdr065.
  • Büchler T, Pavlík T, Bortlíček Z, et al. Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma. Medical Oncology 2012; 29(5): 3321-3324. doi: 10.1007/s12032-012-0293-x.
    Joensuu H, Vehtari A, Riihimäki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. The Lancet Oncology 2012; 13(3): 265-274. doi: 10.1016/S1470-2045(11)70299-6.
  • Poprach A, Bortlíček Z, Büchler T, et al. Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database. Medical Oncology 2012; 29(5): 3314-3320. doi: 10.1007/s12032-012-0286-9.
  • Poprach A, Pavlík T, Melichar B, et al. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. Annals of Oncology 2012; 23(12): 3137-3143. doi: 10.1093/annonc/mds145.
  • Rodger S, Antonova V, Brabec P, et al. CARE-NMD: The role of patient registries in an international study of care in Duchenne muscular dystrophy. Neuromuscular Disorders 2012; 22(9): 880. doi: 10.1016/j.nmd.2012.06.255.
  • Salaj P, Ovesna P, Penka M, et al. Analyses of recombinant activated factor VII treatments from clinical practice for rapid bleeding and acute pain control in haemophilia patients with inhibitors. Haemophilia 2012; 18(6): e409-e411. doi: 10.1111/j.1365-2516.2012.02920.x.
  • Salaj P, Penka M, Smejkal P, et al. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: Haemophilia registry data from the Czech Republic. Thrombosis Research 2012; 129(5): e233-e237. doi: 10.1016/j.thromres.2012.02.005.
  • Studnička J, Rencová E, Rozsíval P, et al. Effects of treatment change in patients with neovascular age-related macular degeneration; Results from the Czech National Registry. Biomedical Papers 2012; 156(4): 359-364. doi: 10.5507/bp.2012.100.
  • Vohanka S, Mazanec R, Pavlovska L, et al. ReaDY: The Czech national registry of myotonic disorders. Neuromuscular Disorders 2012; 22(9): 881-882.
  • Vry J, Gramsch K, Rodger S, et al. Current care practice in Duchenne Muscular Dystrophy in Europe - results of the CARE-NMD cross-sectional survey. Neuromuscular Disorders 2012; 22(9): 886-887. doi: 10.1016/j.nmd.2012.06.259.
  • Blatný J, Seidlová D, Penka M, et al. Severe postpartum haemorrhage treated with recombinant activated Factor VII in 80 Czech patients: analysis of the UniSeven registry. International Journal of Obstetric Anesthesia 2011; 20(4): 367-368. doi: 10.1016/j.ijoa.2011.07.008.
  • Faber E, Mužík J, Koza V, et al. Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 – a report from the population-based CAMELIA Registry. European Journal of Haematology 2011; 87(2): 157-168. doi: 10.1111/j.1600-0609.2011.01637.x.
  • Voglová J, Mužík J. Faber E, et al. Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia. Neoplasma 2011; 58(3): 256-262. doi: 10.4149/neo_2011_03_256.
  • Žáčková, D, Klamová, H, Dušek, L, et al. Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials? American Journal of Hematology 2011; 86(3): 318-321. doi: 10.1002/ajh.21942.
  • Zdziarska J, Chojnowski K, Klukowska A, et al. Registry of inherited bleeding disorders in Poland - current status and potential role of the HemoRec database. Haemophilia 2011; 17(1): e189-e195. doi: 10.1111/j.1365-2516.2010.02371.x.
  • Brabec P, Šufliarsky J, Linke Z, et al. A whole population study of gastrointestinal stromal tumors in the Czech Republic and Slovakia. Neoplasma 2009; 56(5): 459-464. doi: 10.4149/neo_2009_05_459.
  • Brabec P, Vondráček P, Klimeš D, et al. Characterization of the DMD/BMD patient population in Czech Republic and Slovakia using an innovative registry approach. Neuromuscular Disorders 2009; 19(4): 250-254. doi: 10.1016/j.nmd.2009.01.005.
  • Holzerová M, Faber E, Veselovská J, et al. Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results. Cancer Genetics and Cytogenetics 2009; 191(1): 1-9. doi: 10.1016/j.cancergencyto.2008.12.013.
  • Puetz J, Darling G, Brabec P, et al. Thrombotic events in neonates receiving recombinant factor VIIa or fresh frozen plasma. Pediatric Blood & Cancer 2009; 53(6): 1074-1078. doi: 10.1002/pbc.22160.
  • Salaj P, Brabec P, Penka M, et al. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia 2009; 15(3): 752-759. doi: 10.1111/j.1365-2516.2009.02007.x.
  • Smejkal P, Brabec P, Matyskova M, et al. FEIBA((R)) in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre. Haemophilia 2009; 15(3): 743-751. doi: 10.1111/j.1365-2516.2009.02012.x.

 


Zpět